{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:38:44Z","timestamp":1772991524775,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Previous studies show that long noncoding RNA intersectin\u00a01-2 (lnc-ITSN1-2) promotes the inflammation process and serves as a potential biomarker in autoimmune diseases, except for ankylosing spondylitis (AS). Therefore, this study aimed to explore the correlation of baseline lnc-ITSN1-2 expression with disease risk and activity of AS, and to investigate its longitudinal change with treatment response to a tumour necrosis factor alpha (TNF\u03b1) inhibitor in patients with AS. In total, 63 patients with AS receiving 12-week adalimumab treatment were included and their baseline clinical features were collected. Lnc-ITSN1-2 expression in peripheral blood mononuclear cells (PBMC) of patients with AS was detected by reverse transcription quantitative polymerase chain reaction. Meanwhile, Assessment in Spondyloarthritis International Society (ASAS) 40 response was evaluated at week\u00a02 (W2), W4, W8, and W12. According to the ASAS40 response status at W12, patients with AS were classified into responders and non-responders. PBMC lnc-ITSN1-2 expression was also determined in healthy controls (<jats:italic>N<\/jats:italic>\u2009=\u200960). Lnc-ITSN1-2 expression was elevated in patients with AS compared to controls (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Baseline lnc-ITSN1-2 expression was positively associated with C-reaction protein (CRP) (<jats:italic>P<\/jats:italic>\u2009=\u20090.021), interleukin (IL)-1\u03b2 (<jats:italic>P<\/jats:italic>\u2009=\u20090.020), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score (<jats:italic>P<\/jats:italic>\u2009=\u20090.040), and Ankylosing Spondylitis Disease Activity score with C-reactive protein (ASDAS<jats:sub>CRP<\/jats:sub>) (<jats:italic>P<\/jats:italic>\u2009=\u20090.045) in patients with AS. Furthermore, lnc-ITSN1-2 expression declined during the treatment with adalimumab (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Notably, this reduction was more obvious in responders than non-responders. In conclusion, declined lnc-ITSN1-2 expression during the TNF\u03b1 inhibitor treatment correlates with good treatment efficacy in patients with AS, suggesting its clinical value for AS management.<\/jats:p>","DOI":"10.1007\/s10787-021-00854-3","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T05:11:32Z","timestamp":1629263492000},"page":"1371-1378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long noncoding RNA intersectin\u00a01-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis"],"prefix":"10.1007","volume":"29","author":[{"given":"Mingwu","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-6212","authenticated-orcid":false,"given":"Xianjie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"854_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-981-10-5203-3_2","volume":"1008","author":"VS Akhade","year":"2017","unstructured":"Akhade VS, Pal D, Kanduri C (2017) Long noncoding RNA: genome organization and mechanism of action. Adv Exp Med Biol 1008:47\u201374. https:\/\/doi.org\/10.1007\/978-981-10-5203-3_2","journal-title":"Adv Exp Med Biol"},{"key":"854_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225552","author":"D Cici","year":"2019","unstructured":"Cici D, Corrado A, Rotondo C, Cantatore FP (2019) Wnt signaling and biological therapy in rheumatoid arthritis and spondyloarthritis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20225552","journal-title":"Int J Mol Sci"},{"issue":"1\u2013334","key":"854_CR3","doi-asserted-by":"publisher","first-page":"v","DOI":"10.3310\/hta20090","volume":"20","author":"M Corbett","year":"2016","unstructured":"Corbett M, Soares M, Jhuti G et al (2016) Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess 20(1\u2013334):v\u2013vi. https:\/\/doi.org\/10.3310\/hta20090","journal-title":"Health Technol Assess"},{"key":"854_CR4","first-page":"10451","volume":"10","author":"X Gong","year":"2017","unstructured":"Gong X,  Fan X, Zhang Z et al (2017) Circulating lnc-ITSN1-2 expression presents a high value in diagnosis of rheumatoid arthritis and correlates with disease activity. Int J Clin Exp Pathol 10:10451\u201310458","journal-title":"Int J Clin Exp Pathol"},{"key":"854_CR5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/cei.13112","volume":"192","author":"B Gorovits","year":"2018","unstructured":"Gorovits B, Baltrukonis DJ, Bhattacharya I et al (2018) Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol 192:348\u2013365. https:\/\/doi.org\/10.1111\/cei.13112","journal-title":"Clin Exp Immunol"},{"key":"854_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method Methods 25:402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262","journal-title":"Method Methods"},{"key":"854_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005468.pub2","author":"LJ Maxwell","year":"2015","unstructured":"Maxwell LJ, Zochling J, Boonen A et al (2015) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD005468.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"854_CR8","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3389\/fimmu.2020.00852","volume":"11","author":"J Nie","year":"2020","unstructured":"Nie J, Zhao Q (2020) Lnc-ITSN1-2, derived from RNA sequencing, correlates with increased disease risk, activity and promotes CD4(+) T cell activation, proliferation and Th1\/Th17 cell differentiation by serving as a ceRNA for IL-23R via sponging miR-125a in inflammatory bowel disease. Front Immunol 11:852. https:\/\/doi.org\/10.3389\/fimmu.2020.00852","journal-title":"Front Immunol"},{"key":"854_CR9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3906\/sag-1401-79","volume":"45","author":"I Sari","year":"2015","unstructured":"Sari I, Ozturk MA, Akkoc N (2015) Treatment of ankylosing spondylitis Turk J Med Sci 45:416\u2013430. https:\/\/doi.org\/10.3906\/sag-1401-79","journal-title":"Turk J Med Sci"},{"issue":"Suppl 2","key":"854_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X et al (2009) The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68(Suppl 2):1\u201344. https:\/\/doi.org\/10.1136\/ard.2008.104018","journal-title":"Ann Rheum Dis"},{"key":"854_CR11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M et al (2013) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72:815\u2013822. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201766","journal-title":"Ann Rheum Dis"},{"key":"854_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11882-014-0489-6","volume":"15","author":"JA Smith","year":"2015","unstructured":"Smith JA (2015) Update on ankylosing spondylitis: current concepts in pathogenesis. Curr Allergy Asthma Rep 15:489. https:\/\/doi.org\/10.1007\/s11882-014-0489-6","journal-title":"Curr Allergy Asthma Rep"},{"key":"854_CR13","first-page":"1","volume":"36","author":"R Terenzi","year":"2018","unstructured":"Terenzi R, Monti S, Tesei G, Carli L (2018) One year in review 2017: spondyloarthritis. Clin Exp Rheumatol 36:1\u201314","journal-title":"Clin Exp Rheumatol"},{"key":"854_CR14","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136\u20132146. https:\/\/doi.org\/10.1002\/art.21913","journal-title":"Arthritis Rheum"},{"key":"854_CR15","first-page":"4650","volume":"11","author":"T Yue","year":"2019","unstructured":"Yue T, Fan X, Zhang Z et al (2019) Downregulation of lncRNA ITSN1-2 correlates with decreased disease risk and activity of rheumatoid arthritis (RA), and reduces RA fibroblast-like synoviocytes proliferation and inflammation via inhibiting NOD2\/RIP2 signaling pathway. Am J Transl Res 11:4650\u20134666","journal-title":"Am J Transl Res"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-021-00854-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-021-00854-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-021-00854-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T22:16:54Z","timestamp":1634163414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-021-00854-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1007\/s10787-021-00854-3","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"10 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}